Thomas Harding
Impact in
- Oncology top 10%
- Lymphatic System and Diseases
- Cancer Cells and Metastasis
-
- Nuclear Receptors and Signaling
Papers in
- Oncology 11
- CAR-T cell therapy research 2
- PARP inhibition in cancer therapy 2
- Cancer Immunotherapy and Biomarkers 2
-
- Prostate Cancer Treatment and Research 6
- Prostate Cancer Diagnosis and Treatment 5
- Co-authors
- Karin Jooss (4 shared papers)Jörg B. Schulz (1 shared paper)James B. Uney (1 shared paper)Xu Xia (1 shared paper)Michael Weller (1 shared paper)Seppo Ylä‐Herttuala (1 shared paper)Iiro Rajantie (1 shared paper)Michael Jeltsch (1 shared paper)
- Journals
- Cancer Research (4 papers)European Journal of Cancer (2 papers)Annals of Oncology (2 papers)Molecular Therapy (1 paper)Poultry Science (1 paper)
- Partner nations
- United StatesUnited KingdomFinland
In The Last Decade
Thomas Harding
21 papers receiving 742 citations
Peers
Comparison fields: 5 of 83
- Oncology 332
- Cellular and Molecular Neuroscience 122
- Animal Science and Zoology 63
- Neurology 90
- Molecular Biology 378
Countries citing papers authored by Thomas Harding
This map shows the geographic impact of Thomas Harding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Harding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Harding more than expected).
Fields of papers citing papers by Thomas Harding
This network shows the impact of papers produced by Thomas Harding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Harding. The network helps show where Thomas Harding may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Harding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 317 | |
| 2 | 2001 | 195 | |
| 3 | 1997 | 101 | |
| 4 | 2020 | 41 | |
| 5 | 2009 | 34 | |
| 6 | 2021 | 21 | |
| 7 | 2015 | 13 | |
| 8 | 2006 | 8 | |
| 9 | 2024 | 7 | |
| 10 | 2024 | 5 | |
| 11 | 2024 | 4 | |
| 12 | 2022 | 4 | |
| 13 | 2016 | 3 | |
| 14 | 2016 | 2 | |
| 15 | 2022 | 2 | |
| 16 | Identification of antibody responses induced in patients with metastatic hormone-refractory prostate cancer (HRPC) treated with a GM-CSF-transduced allogeneic prostate cancer immunotherapy | 2007 | 1 |
| 17 | 2017 | 1 | |
| 18 | 2005 | 1 | |
| 19 | 2023 | 1 | |
| 20 | 2022 | 1 |
About Thomas Harding
Thomas Harding is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Genetics and Immunology, having authored 22 papers that have together received 764 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (6 papers), Prostate Cancer Diagnosis and Treatment (5 papers), Virus-based gene therapy research (3 papers), Immunotherapy and Immune Responses (3 papers), Parkinson's Disease Mechanisms and Treatments (2 papers), CAR-T cell therapy research (2 papers), PARP inhibition in cancer therapy (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). The work is most often cited by research in Oncology (332 citations), Cellular and Molecular Neuroscience (122 citations), Animal Science and Zoology (63 citations), Neurology (90 citations) and Molecular Biology (378 citations). Thomas Harding has collaborated with scholars based in United States, United Kingdom and Finland. Frequent co-authors include Karin Jooss, Jörg B. Schulz, James B. Uney, Xu Xia, Michael Weller, Seppo Ylä‐Herttuala, Iiro Rajantie, Michael Jeltsch, Yulong He and Katri Pajusola. Their work appears in journals such as Cancer Research, European Journal of Cancer, Annals of Oncology, Molecular Therapy and Poultry Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.